In a prior randomized controlled study, patients treated with ulipristal acetate (UPA) or placebo for 3 months had a decrease in leiomyoma size. A total of 10 patients’ tissue samples (5 placebo and 5 treated with 10 mg/d UPA) that underwent hysterectomy and tissue preservation were identified from this study. Quantitative real-time reverse transcriptase polymerase chain reaction and Western blotting were used to assess fold gene and protein expression of extracellular membrane (ECM) proteins: collagen 1A (COL1A), fibronectin (FN1), and versican (VCAN) of the samples. Confirmatory immunohistochemical analysis was performed. Changes in total matrix collagen were examined using Masson trichrome staining. Multiplex measurement of the matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases was performed. Compared to placebo-treated surgical specimens, 80% of the treated specimens showed decrease in VCAN protein, 60% showed decrease in FN1, but no consistent alteration in COL1A. This effect was also supported by immunohistochemistry where leiomyoma surgical specimens demonstrated decreased amount of FN1 and VCAN on UPA treatment. Increased MMP2 and decreased MMP9 in treated patient leiomyomas indicate both degradation of the matrix and inhibition of the pathway involved in matrix production. Treatment with UPA decreased fibroid volume in placebo-controlled, randomized trials. Treatment with UPA decreased gene expression and protein production in leiomyoma tissue, suggesting both an impact on water content and ECM protein concentration as a mechanism of ulipristal-mediated decrease in leiomyoma size.
BairdDDDunsonDBHillMCCousinsDSchectmanJM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obset Gynecol. 2003;188(1):100–107.
2.
BartelsCBCaytonKCChuongFS. An evidence-based approach to the medical management of fibroids: a systematic review. Clin Obstet Gynecol. 2016;59(1):30–52.
3.
WalkerCLStewartEA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589–1592.
4.
PaysonMLeppertPSegarsJ. Epidemiology of myomas. Obset Gynecol Clin N Am. 2006;33(1):1–11.
5.
MyersERBarberMDGustilo-AshbyTCouchmanGMatcharDBMcCroryDC. Management of uterine leiomyomata: what do we really know?Obstet Gynecol. 2002;100(1):8–17.
6.
LevensEDPotlog-NahariCArmstrongAY. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(5):1129–1136.
7.
NiemanLKBlockerWNanselT. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 2011;95(2):767–772.
DonnezJTatarchukTFBouchardP; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–420.
10.
DonnezJTomaszewskiJVazquezF; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–432.
11.
DonnezJHudecekRDonnezO. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103(2):519–527.
RosatoEFarrisMBastianelliC. Mechanism of action of ulipristal acetate for emergency contraception: a systematic review. Front Pharmacol. 2016;6:315.
15.
LeppertPCCatherinoWHSegarsJH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obset Gynecol. 2006;195(2):415–420.
16.
MalikMNorianJMcCarthy-KeithDBrittenJCatherinoWH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Sem Reprod Med. 2010;28(3):169–179.
17.
CheginiN. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med. 2010;28(3):180–203.
18.
NorianJMMalikMParkerCY. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16(12):1153–1164.
19.
FujisawaCCastellotJJr. Matrix production and remodeling as therapeutic targets for uterine leiomyoma. J Cell Commun Signal. 2014;8(3):179–194.
20.
XuQOharaNLiuJ. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008;14(3):181–191.
21.
XuQOharaNChenW. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod. 2006;21(9):2408–2416.
22.
XuQTakekidaSOharaN. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005;90(2):953–961.
23.
MalikMCatherinoWH. Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays. Fertil Steril. 2007;87(5):1166–1172.
24.
PaysonMMalikMSiti-Nur MorrisSSegarsJHChasonRCatherinoWH. Activating transcription factor 3 gene expression suggests that tissue stress plays a role in leiomyoma development. Fertil Steril. 2009;92(2):748–755.
25.
MalikMBrittenJSegarsJCatherinoWH. Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a rho-kinase inhibitor, when compared to 2-dimensional cultures. Reprod Sci. 2014;21(9):1126–1138.
26.
CatherinoWSalamaAPotlog-NahariCLeppertPTsibrisJSegarsJ. Gene expression studies in leiomyomata: new directions for research. Semin Reprod Med. 2004;22(2):83–90.
27.
BarkerNMCarrinoDACaplanAI. Proteoglycans in leiomyoma and normal myometrium: abundance, steroid hormone control, and implications for pathophysiology. Reprod Sci. 2016;23(3):302–309.
28.
FlakeGPMooreABSuttonD. The natural history of uterine leiomyomas: light and electron microscopic studies of fibroid phases, interstitial ischemia, inanosis, and reclamation. Obstet Gynecol Int. 2013;2013:528376.
29.
BouchardPChabbert-BuffetNFauserB. Selective progeterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175–1189.
30.
MelisGBPirasBMarottoMF. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin Drug Metab Toxicol. 2012;8(7):901–908.
31.
ChwaliszKPerezMCDeMannoDWinkelCSchubertGElgerW. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26(3):423–438.
32.
CourtoyGEDonnezJMarbaixEDolmansMM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104(2):426–434.e1.
33.
DouQTarnuzzerRWWilliamsRSSchultzGSCheginiN. Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression. Mol Hum Reprod. 1997;3(11):1005–1014.
34.
PalmerSSHaynes-JohnsonDDiehlTNowakRA. Increased expression of stromelysin 3 mRNA in leiomyomas (uterine fibroids) compared with myometrium. J Soc Gynecol Investig. 1998;5(4):203–209.
35.
BogusiewiczMStryjecka-ZimmerMPostawskiKJakimiukAJRechbergerT. Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol. 2007;23(9):541–546.
36.
KorompelisPPiperiCAdamopoulosC. Expression of vascular endothelial factor-A, gelatinases (MMP-2, MMP-9) and TIMP-1 in uterine leiomyomas. Clin Chem Lab Med. 2015;53(9):1415–1424.
37.
WolańskaMSobolewskiKBańkowskiEJaworskiS. Matrix metalloproteinases of human leiomyoma in various stages of tumor growth. Gynecol Obstet Invest. 2004;58(1):14–18.
38.
HalderSKOsteenKGAl-HendyA. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013;28(9):2407–2416.
39.
GiannandreaMParksWC. Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech. 2014;7(2):193–203.
40.
ParksWCWilsonCLLópez-BoadoYS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4(8):617–629.
41.
ZuoFKaminskiNEuguiE. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A. 2002;99(9):6292–6297.
42.
YuQStamenkovicI. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14(2):163–176.
43.
DayerCStamenkovicI. Recruitment of matrix metalloproteinase-9 (MMP-9) to the fibroblast cell surface by lysyl hydroxylase 3 (LH3) triggers transforming growth factor-β (TGF-β) activation and fibroblast differentiation. J Biol Chem. 2015;290(22):13763–13778.
44.
CiarmelaPCarrarelliPIslamMS. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells. Reprod Sci. 2014;21(9):1120–1125.
45.
McCarthy-KeithDMalikMBrittenJSegarsJCatherinoW. Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells. Fertil Steril. 2011;95(7):2383–2387.
